Martin Stogniew
Corporate Officer/Principal chez Oncoceutics, Inc.
Profil
Martin Stogniew is currently the Chief Development Officer at Oncoceutics, Inc. He previously worked as the Executive Vice President-Scientific Affairs at Vicuron Pharmaceuticals LLC and as the Vice President-Pharmaceutical Sciences at Ceptaris Therapeutics, Inc. Dr. Stogniew obtained his undergraduate and doctorate degrees from the University of Maryland.
Postes actifs de Martin Stogniew
| Sociétés | Poste | Début |
|---|---|---|
Oncoceutics, Inc.
 Oncoceutics, Inc. Pharmaceuticals: MajorHealth Technology Oncoceutics, Inc. operates as a clinical-stage biopharmaceutical company. It is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The firm develops technology and therapies including ONC201, for natural potent tumor suppressor pathways in human cancer. Oncoceutics was founded by Wafik El-Deiry, Wolfgang Oster and Lee T. Schalop in 2009 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | 01/01/2012 |
Anciens postes connus de Martin Stogniew
| Sociétés | Poste | Fin |
|---|---|---|
Ceptaris Therapeutics, Inc.
 Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Corporate Officer/Principal | - |
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Directeur Technique/Scientifique/R&D | - |
Formation de Martin Stogniew
| University of Maryland | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Health Technology |
Oncoceutics, Inc.
Oncoceutics, Inc. Pharmaceuticals: MajorHealth Technology Oncoceutics, Inc. operates as a clinical-stage biopharmaceutical company. It is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The firm develops technology and therapies including ONC201, for natural potent tumor suppressor pathways in human cancer. Oncoceutics was founded by Wafik El-Deiry, Wolfgang Oster and Lee T. Schalop in 2009 and is headquartered in Philadelphia, PA. | Health Technology |
